Submitted by Anonymous (not verified) on 11 May 2026 - 15:03
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 5, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 5, Status: Authorised